BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login
search help

Search Results

Documents 1-25 out of 41 found
  Current Search:  poly: 41, rx: 413     

HTML
58%
Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
- Oralair(R) Grasses 300IR Highly Positive Clinical Results in a Pharmacodynamic Study Conducted in an Allergen Challenge Chamber Stallergenes S.A.

announces the highly positive results of a new study conducted in an Allergen Challenge...

KRON4:  Aug 28 2008 10:59AM
Matching: poly
Find similar documents
HTML
58%
Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
- Oralair(R) Grasses 300IR Highly Positive Clinical Results in a Pharmacodynamic Study Conducted in an Allergen Challenge Chamber Stallergenes S.A.

announces the highly positive results of a new study conducted in an Allergen Challenge...

KLFY:  Aug 27 2008 9:34PM
Matching: poly
Find similar documents
HTML
58%
Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
- Oralair(R) Grasses 300IR Highly Positive Clinical Results in a Pharmacodynamic Study Conducted in an Allergen Challenge Chamber Stallergenes S.A.

announces the highly positive results of a new study conducted in an Allergen Challenge...

Pharma Live:  Aug 27 2008 7:51PM
Matching: poly
Find similar documents
HTML
58%
Ed Blonz: Unproven cancer treatment preys on hope
Q: The father of a close friend has bladder cancer, and he has been downing a daily dose of a product called Poly-MVA.

There is concern in the family, and I told her I would check with my sources.

I have not found much on this.

Inside Bay Area:  Aug 19 2008 5:10PM
Matching: poly
Find similar documents
HTML
58%
High Levels of Cancer-Causing Chemicals Found in Donna Lake
HIDALGO COUNTY - Federal officials warn everyone not to eat fish caught in Donna Lake or the irrigation canals, because they contain high levels of chemicals known to cause cancer.

The government has yet to figure where the chemicals are...

KRGV:  Aug 14 2008 2:49PM
Matching: poly
Find similar documents
HTML
58%
Nventa Biopharmaceuticals Corporation Announces Second Quarter 2008 Loss
-(T-Net)--Nventa Biopharmaceuticals (TSX: NVN) announced today financial results for the second quarter and six months ended June 30, 2008, and highlighted several recent product developments and corporate milestones.

Recent product and...

BC Technology:  Aug 12 2008 11:30PM
Matching: poly
Find similar documents
HTML
58%
Nventa Biopharmaceuticals Corporation Announces Second Quarter 2008 Financial Results and Recent Corporate Hig
SAN DIEGO, Aug.

12 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation announced today financial results for the second quarter and six months ended June 30, 2008, and highlighted several recent product developments and...

KOTA Territory News:  Aug 12 2008 12:03PM
Matching: poly
Find similar documents
HTML
58%
Nventa Biopharmaceuticals Corporation Announces Second Quarter 2008 Financial Results and Recent Corporate Hig
SAN DIEGO, Aug.

12, 2008 /CNW/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today financial results for the second quarter and six months ended June 30, 2008, and highlighted several recent product developments and...

Pharma Live:  Aug 12 2008 4:23PM
Matching: poly
Find similar documents
HTML
58%
Nventa Biopharmaceuticals Corporation Announces Second Quarter 2008 Financial Results and Recent Corporate Hig
- 07:45 EST SAN DIEGO, Aug.

12 /CNW/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today financial results for the second quarter and six months ended June 30, 2008, and highlighted several recent product developments and...

Canadian Business Magazine:  Aug 12 2008 12:23PM
Matching: poly
Find similar documents
HTML
58%
Nventa Biopharmaceuticals Corporation Announces Second Quarter 2008 Financial Results and Recent Corporate Hig
SAN DIEGO, Aug.

12 CA-Nventa-earnings SAN DIEGO, Aug.

12 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today financial results for the second quarter and six months ended June 30, 2008, and...

Earthtimes.org:  Aug 12 2008 11:52AM
Matching: poly
Find similar documents
HTML
58%
Nventa Biopharmaceuticals Corporation Announces Second Quarter 2008 Financial Results and Recent Corporate Hig
SAN DIEGO, Aug.

12 /CNW/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN - News) announced today financial results for the second quarter and six months ended June 30, 2008, and highlighted several recent product developments and...

Yahoo! Canada:  Aug 12 2008 11:49AM
Matching: poly
Find similar documents
HTML
58%
Nventa Biopharmaceuticals Corporation Announces Second Quarter 2008 Financial Results and Recent Corporate Hig
SAN DIEGO, Aug.

12 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX:NVN) announced today financial results for the second quarter and six months ended June 30, 2008, and highlighted several recent product developments...

Houston Chronicle:  Aug 12 2008 11:38AM
Matching: poly
Find similar documents
HTML
58%
Nventa Biopharmaceuticals Corporation Announces Second Quarter 2008 Financial
SAN DIEGO, August 12 /PRNewswire/ -- Nventa Biopharmaceuticals Corporation (News) (TSX: NVN) announced today financial results for the second quarter and six months ended June 30, 2008, and highlighted several recent product developments and...
FinanzNachrichten.de:  Aug 12 2008 11:38AM
Matching: poly
Find similar documents
HTML
58%
Nventa Announces Final Data from HspE7 Phase 1 Cervical Dysplasia Trial
- Nventa Biopharmaceuticals Corporation announced that it has completed analysis of immunological data from all four cohorts of its Phase 1 clinical trial for HspE7, its lead product candidate.

HspE7 is a therapeutic treatment for patients...

Bionity.com:  Jul 30 2008 12:13AM
Matching: poly
Find similar documents
HTML
58%
Nventa reports positive results from Phase I cervical dysplasia trial
Nventa Biopharmaceuticals has completed analysis of immunological data from all four cohorts of its Phase I clinical trial for HspE7, its lead product candidate for treatment of patients with cervical intraepithelial neoplasia or CIN, a...
Datamonitor:  Jul 30 2008 1:48PM
Matching: poly
Find similar documents
HTML
58%
Nventa reports positive results from Phase I cervical dysplasia trial
The purpose of the Phase I trial was to determine the safety, tolerability and immunogenicity of HspE7 plus escalating doses of adjuvant (50, 500, 1,000 and 2,000mcg of Poly-ICLC).

All dose regimens were found to be safe and well...

Pharmaceutical Business Review:  Jul 30 2008 1:25PM
Matching: poly
Find similar documents
HTML
58%
Nventa Wins European Patent Challenge Covering Lead Product Candidate HspE7 and Other HPV Therapeutics
/PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation announced today that it has received a favorable decision from the Technical Board of Appeal of the European Patent Office (EPO) for the company's European Patent Number 1,002...
Pharmalive.com:  Jul 30 2008 3:17AM
Matching: poly
Find similar documents
HTML
58%
HST Global, Inc. Sets New Standards in the Treatment of Stage IV Breast Cancer!
(Prudent Press Agency)---HAMPTON, Va.--HST Global, Inc., (OTCBB: HTSC) announced today it is meeting with 72% efficacy in pre-clinical treatment of Stage IV cancer in a test of 250 patients.

The highlight of the study is in stage IV breast...

Prudent Press Agency:  Jul 29 2008 10:59PM
Matching: poly
Find similar documents
HTML
58%
Nventa Announces Final Data from HspE7 Phase 1 Cervical Dysplasia Trial
SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation today announced that it has completed analysis of immunological data from all four cohorts of its Phase 1 clinical trial for HspE7, its lead product candidate...
SmartBrief:  Jul 29 2008 10:05AM
Matching: poly
Find similar documents
HTML
58%
Nventa Announces Final Data from HspE7 Phase 1 Cervical Dysplasia Trial
-- Company Provides Update to Phase 2 Development Plan -- SAN DIEGO, July 28, 2008 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation today announced that it has completed analysis of immunological data from all four cohorts of...
Pharma Live:  Jul 29 2008 3:29PM
Matching: poly
Find similar documents
HTML
58%
Nventa Announces Final Data from HspE7 Phase 1 Cervical Dysplasia Trial
Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that it has completed analysis of immunological data from all four cohorts of its Phase 1 clinical trial for HspE7, its lead product candidate.

HspE7 is a therapeutic...

Freshnews.com:  Jul 29 2008 10:10AM
Matching: poly
Find similar documents
HTML
58%
Nventa Wins European Patent Challenge Covering Lead Product Candidate HspE7 and Other HPV Therapeutics
/PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation announced today that it has received a favorable decision from the Technical Board of Appeal of the European Patent Office (EPO) for the company's European Patent Number 1,002...
Pharma Live:  Jul 29 2008 6:14PM
Matching: poly
Find similar documents
HTML
58%
As Neros Moves to Change Pharma Industry
(This Day/All Africa Global Media via COMTEX News Network) -- The company, Neros Pharmaceuticals, is not new to the drug sector in the country.

After years of operations in the marketing of over 71 pharmaceutical brands in the country, the...

Calibre Macro World:  Jul 29 2008 4:17PM
Matching: poly
Find similar documents
HTML
58%
CORRECTING and REPLACING HST Global, Inc. Sets New Standards in the Treatment of Stage IV Breast Cancer!
HST GLOBAL, INC.

SETS NEW STANDARDS IN THE TREATMENT OF STAGE IV BREAST CANCER!

HST Global, Inc., (OTCBB: HSTC) announced today it is meeting with 72% efficacy in pre-clinical treatment of Stage IV cancer in a test of 250 patients!

The...

Genetic Engineering News:  Jul 29 2008 4:05PM
Matching: poly
Find similar documents
HTML
58%
CORRECTING and REPLACING HST Global, Inc. Sets New Standards in the Treatment of Stage IV Breast Cancer!
Company Website: http://www.hstglobal.com HAMPTON, Va.

-- (Business Wire) Reissuing release to correct ticker symbol for searching purposes.

The correctedrelease reads: HST GLOBAL, INC.

SETS NEW STANDARDS IN THE TREATMENT OF STAGE IV...

Stockwatch:  Jul 29 2008 3:28PM
Matching: poly
Find similar documents

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.